Autor: "Garbe, Claus" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
Autorzy:: Meraz-Torres F; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Niessner H; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) Image Guided and Functionally Instructed Tumor Therapies, University Hospital Tübingen, Tübingen, 72076, Germany.
Plöger S; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Riel S; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Schörg B; Department of Preclinical Imaging and Radiopharmacy, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, University of Tübingen, Tübingen, 72076, Germany.
Casadei N; NGS Competence Center Tübingen, Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Kneilling M; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) Image Guided and Functionally Instructed Tumor Therapies, University Hospital Tübingen, Tübingen, 72076, Germany.; Department of Preclinical Imaging and Radiopharmacy, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, University of Tübingen, Tübingen, 72076, Germany.
Schaller M; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Flatz L; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Macek B; Proteome Center Tübingen, University of Tübingen, Tübingen, Germany.
Eigentler T; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany.
Rieß O; NGS Competence Center Tübingen, Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Garbe C; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.
Amaral T; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany.; Cluster of Excellence iFIT (EXC 2180) Image Guided and Functionally Instructed Tumor Therapies, University Hospital Tübingen, Tübingen, 72076, Germany.
Sinnberg T; Department of Dermatology, Tübingen University Hospital, Tübingen, Germany. .; Cluster of Excellence iFIT (EXC 2180) Image Guided and Functionally Instructed Tumor Therapies, University Hospital Tübingen, Tübingen, 72076, Germany. .; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Jan 23; Vol. 43 (1), pp. 30. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:: Journal Article
MeSH Terms:: Disulfiram*
Melanoma*
Humans ; Animals ; Mice ; Proto-Oncogene Proteins B-raf ; Copper ; Ditiocarb ; Disease Models, Animal ; Mitogen-Activated Protein Kinase Kinases

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Autorzy:: Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Agarwala SS; Temple University School of Medicine, Philadelphia, PA, USA.
Warner AB; Stanford University School of Medicine, Stanford, CA, USA.
Ernstoff MS; ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Cancer Therapy and Diagnosis Division, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Fox BA; Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA.
Galon J; INSERM, Laboratory of Integrative Cancer Immunology, 75006, Paris, France.; Centre de Recherche Des Cordeliers, Sorbonne Université, Université de Paris, Paris, France.; Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Garbe C; Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
Gastman BR; Department of Surgery, School of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kalinski P; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Krogsgaard M; Laura and Isaac Perlmutter Cancer Center and Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Leidner RS; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Menzies AM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.
Michielin O; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Poulikakos PI; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Weber JS; Laura and Isaac Perlmutter Cancer Center, a NCI-Funded Comprehensive Cancer Center, NYU School of Medicine, New York, NY, USA.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy.
Osman I; Rudolf L, Baer, New York University Langone Medical Center, New York, NY, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thurin M; Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institute of Health (NIH), Bethesda, MD, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2023 Jul 28; Vol. 21 (1), pp. 508. Date of Electronic Publication: 2023 Jul 28.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma*/therapy
Melanoma*/drug therapy
Humans ; Immunotherapy ; CTLA-4 Antigen ; Italy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
Autorzy:: Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Blank C; Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eggermont AM; University Medical Center Utrecht & Princess Maxima Center, Utrecht, The Netherlands.; Comprehensive Cancer Center München, Technical University München & Ludwig Maximiliaan University, München, Germany.
Garbe C; Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Hauschild A; Department of Dermatology, University of Kiel, Kiel, Germany.
Luke JJ; University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA.
Mehnert JM; Perlmutter Cancer Center of NYU Langone/NYU Grossman School of Medicine, New York, NY, USA.
Sosman JA; Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical Center, Chicago, IL, USA.
Tawbi HA; MD Anderson Brain Metastasis Clinic UT, MD Anderson Cancer Center, Houston, TX, USA.
Mandalà M; University of Perugia, Perugia, Italy.
Testori A; Image regenerative clinic Milan, Italy; EORTC Melanoma Group, Brussels, Belgium.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy.
Osman I; Rudolf L. Baer, NYU Langone Medical Center, New York, NY, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2023 Apr 18; Vol. 21 (1), pp. 265. Date of Electronic Publication: 2023 Apr 18.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma*/drug therapy
Melanoma*/genetics
Skin Neoplasms*
Humans ; Immunotherapy ; Ipilimumab/therapeutic use ; Combined Modality Therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Autorzy:: Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Agarwala SS; Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA.
Blank C; Netherlands Cancer Institute, Amsterdam, Netherlands.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy.
Carvajal RD; Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Ernstoff MS; Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA.
Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA.
Garbe C; Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany.
Grob JJ; Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France.
Hamid O; Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA.
Krogsgaard M; New York Grossman School of Medicine, New York University Langone, New York, NY, USA.
Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Lund AW; Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA.
Madonna G; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Michielin O; Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Neyns B; Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Osman I; New York University Langone Medical Center, New York, NY, USA.
Peters S; UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland.
Poulikakos PI; Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Quezada SA; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK.
Reinfeld B; Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Zitvogel L; Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2022 Sep 04; Vol. 20 (1), pp. 391. Date of Electronic Publication: 2022 Sep 04.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*
Melanoma*/genetics
Biomarkers ; Humans ; Immunotherapy/methods ; Italy ; Pandemics ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Autorzy:: Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Instituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. .
Blank C; Netherlands Cancer Institute, Amsterdam, The Netherlands.
Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
Ernstoff MS; Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, USA.
Ferrone S; Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.
Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA.
Garbe C; Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany.
Hwu P; Moffitt Cancer Center, Tampa, FL, USA.
Kalinski P; Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, USA.
Krogsgaard M; Medical School, New York University Langone, New York, NY, USA.
Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Luke JJ; Cancer Immunotherapeutic Center of UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Neyns B; Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Postow MA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
Quezada SA; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK.
Teng MWL; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Trinchieri G; Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Testori A; Image Rigenerative Clinic-Skin Oncology Division, Milan, Italy.; Chairman Surgical Subgroup EORTC Melanoma Group Brussels, Brussels, Belgium.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy.
Osman I; New York University Langone Medical Center, New York, NY, USA.
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2021 Jun 30; Vol. 19 (1), pp. 278. Date of Electronic Publication: 2021 Jun 30.
Typ publikacji:: Congress
MeSH Terms:: Immunotherapy*
Melanoma*/drug therapy
Humans ; Italy ; Molecular Targeted Therapy ; Tumor Microenvironment

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Autorzy:: Wessely A; Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.
Steeb T; Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.
Leiter U; Department of Dermatology, Eberhard Karls University of Tübingen, 72074 Tübingen, Germany.
Garbe C; Department of Dermatology, Eberhard Karls University of Tübingen, 72074 Tübingen, Germany.
Berking C; Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.
Heppt MV; Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2020 Dec 06; Vol. 21 (23). Date of Electronic Publication: 2020 Dec 06.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Squamous Cell/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Carcinoma, Squamous Cell/diagnosis ; Clinical Trials as Topic ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/standards ; Melanoma/diagnosis ; Skin Neoplasms/diagnosis ; Standard of Care

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Autorzy:: Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola, 80131, Naples, Italy. .
Puzanov I; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Agarwala SS; Temple University School of Medicine, Philadelphia, PA, USA.
Blank C; Netherlands Cancer Institute, Amsterdam, The Netherlands.
Carvajal RD; Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Demaria S; Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
Ernstoff M; Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, State University, Buffalo, NY, USA.
Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA.
Gajewski TF; Department of Pathology, University of Chicago, Chicago, IL, USA.; Department of Medicine (Section of Haematology/Oncology), University of Chicago, Chicago, IL, USA.
Garbe C; Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
Hwu P; Department of Melanoma Medical Oncology, Division of Cancer Medicine, Anderson Cancer Center, Houston, TX, USA.
Lo RS; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Long GV; Melanoma Institute Australia, The University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia.
Luke JJ; Medicine University of Chicago, Chicago, IL, USA.
Osman I; The Interdisciplinary Melanoma Program, New York University Langone Medical Center, NYU Grossman Medical School, New York, NY, USA.
Postow MA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Sullivan RJ; Melanoma Program, Mass General Cancer Center, Boston, MA, USA.
Taube JM; Division of Dermatopathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Trinchieri G; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Zarour HM; Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Caracò C; Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2020 Sep 07; Vol. 18 (1), pp. 346. Date of Electronic Publication: 2020 Sep 07.
Typ publikacji:: Journal Article
MeSH Terms:: Immunotherapy*
Melanoma*/therapy
CTLA-4 Antigen ; Combined Modality Therapy ; Humans ; Italy ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Influence of F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach.
Autorzy:: Olthof SC; Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Straβe 3, 72076, Tuebingen, Germany. .
Forschner A; Department of Dermatooncology, University Hospital of Tuebingen, Liebermeisterstraße 25, 72076, Tuebingen, Germany.
Martus P; Institute of Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
Garbe C; Department of Dermatooncology, University Hospital of Tuebingen, Liebermeisterstraße 25, 72076, Tuebingen, Germany.
Nikolaou K; Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Straβe 3, 72076, Tuebingen, Germany.
la Fougère C; Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital of Tuebingen, Otfried-Mueller-Straβe 14, 72076, Tuebingen, Germany.
Gückel B; Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Straβe 3, 72076, Tuebingen, Germany.
Vach W; Department of Orthopaedics and Traumatology, University Hospital of Basel, Spitalstraße 21, 4031, Basel, Switzerland.
Pfannenberg C; Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen, Hoppe-Seyler-Straβe 3, 72076, Tuebingen, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2020 Sep; Vol. 47 (10), pp. 2313-2321. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Fluorodeoxyglucose F18*
Melanoma*/diagnostic imaging
Melanoma*/surgery
Cohort Studies ; Humans ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography ; Prospective Studies ; Radiopharmaceuticals

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy.
Autorzy:: Wagner NB; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Luttermann F; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Gassenmaier M; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Forschner A; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Leiter U; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Garbe C; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.
Eigentler TK; Department of Dermatology and Venereology, University Medical Center Tubingen, University Tubingen, Tubingen, Germany.; Pokaż więcej
Źródło:: The Australasian journal of dermatology [Australas J Dermatol] 2020 Aug; Vol. 61 (3), pp. e310-e318. Date of Electronic Publication: 2020 Feb 12.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma/*blood
Skin Neoplasms/*blood
Aged ; Basophils ; Eosinophils ; Female ; Humans ; Kaplan-Meier Estimate ; Leukocyte Count ; Leukocytes ; Lymphocytes ; Male ; Melanoma/pathology ; Middle Aged ; Monocytes ; Neoplasm Staging ; Neutrophils ; Predictive Value of Tests ; Proportional Hazards Models ; Retrospective Studies ; Sentinel Lymph Node Biopsy ; Skin Neoplasms/pathology ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.
Autorzy:: Glutsch V; Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Str. 2, DE-97080 Würzburg, Germany.
Amaral T
Garbe C
Thoms KM
Mohr P
Hauschild A
Schilling B; Pokaż więcej
Źródło:: Acta dermato-venereologica [Acta Derm Venereol] 2020 Jun 11; Vol. 100 (13), pp. adv00174. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma*/drug therapy
Melanoma*/genetics
Skin Neoplasms*/drug therapy
Skin Neoplasms*/genetics
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Lactate Dehydrogenases ; Mitogen-Activated Protein Kinase Kinases ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Proto-Oncogene Proteins B-raf/genetics ; Pyridones

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Autorzy:: Bochem J; Department of Dermatology, University Medical Center, Tübingen, Germany.
Zelba H; Department of Dermatology, University Medical Center, Tübingen, Germany.
Amaral T; Department of Dermatology, University Medical Center, Tübingen, Germany.; Portuguese Air Force Health Direction, Lisbon, Portugal.
Spreuer J; Department of Dermatology, University Medical Center, Tübingen, Germany.
Soffel D; Department of Dermatology, University Medical Center, Tübingen, Germany.
Eigentler T; Department of Dermatology, University Medical Center, Tübingen, Germany.
Wagner NB; Department of Dermatology, University Medical Center, Tübingen, Germany.
Uslu U; Department of Dermatology, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany.
Terheyden P; Department of Dermatology, University of Lübeck, Lübeck, Germany.
Meier F; Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Garbe C; Department of Dermatology, University Medical Center, Tübingen, Germany.
Pawelec G; Department of Immunology, University of Tübingen, Tübingen, Germany.; Health Sciences North Research Institute, Sudbury, Ontario, Canada.; Division of Cancer Studies, King's College London, London, United Kingdom.; John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.; Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom.
Weide B; Department of Dermatology, University Medical Center, Tübingen, Germany.
Wistuba-Hamprecht K; Department of Dermatology, University Medical Center, Tübingen, Germany.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Aug 16; Vol. 14 (8), pp. e0221301. Date of Electronic Publication: 2019 Aug 16 (Print Publication: 2019).
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents, Immunological/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
T-Lymphocytes/*immunology
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; CD56 Antigen/metabolism ; Female ; Follow-Up Studies ; Humans ; Lymphocyte Count ; Male ; Melanoma/blood ; Melanoma/mortality ; Middle Aged ; Neoplasm Staging ; Nivolumab/therapeutic use ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Progression-Free Survival ; Skin Neoplasms/blood ; Skin Neoplasms/mortality ; T-Lymphocytes/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
Autorzy:: Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Via Mariano Semmola, 80131, Naples, Italy. .
Agarwala SS; Medical Oncology and Hematology, St. Luke's University Hospital and Temple University, Bethlehem, PA, USA.
Botti G; Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
Budillon A; Experimental Pharmacology Unit, Department of Translational Research, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
Davies MA; Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
Ernstoff M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Ferrone S; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Formenti S; Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA.
Gajewski TF; Department of Pathology and Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA.
Garbe C; Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
Hamid O; The Angeles Clinic, Experimental Therapeutics Cedars Sinai Foundation, Los Angeles, CA, USA.
Lo RS; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Luke JJ; University of Chicago Medical Center, Chicago, IL, USA.
Michielin O; Oncology Department, UNIL-CHUV, Lausanne, Switzerland.
Palmieri G; Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy.
Zitvogel L; Institut de Cancérologie, Gustave Roussy Cancer Campus, Villejuif, Paris, France.
Marincola FM; Refuge Biotechnologies, Menlo Park, CA, USA.
Masucci G; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, 9609 Medical Center Drive, Bethesda, MD, 20892-7420, USA. .
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2019 Jul 22; Vol. 17 (1), pp. 234. Date of Electronic Publication: 2019 Jul 22.
Typ publikacji:: Congress
MeSH Terms:: Melanoma/*pathology
Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; Drug Resistance, Neoplasm ; Exosomes/metabolism ; Humans ; Immunotherapy ; Italy ; Melanoma/immunology ; Melanoma/therapy ; Neoplasm Staging

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
Autorzy:: Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Via Mariano Semmola snc, 80131, Naples, NA, Italy. .
Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Agarwala SS; Medical Oncology and Hematology, St. Luke's University Hospital and Temple University, Bethlehem, PA, USA.
Bifulco C; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA.
Botti G; Istituto Nazionale Tumori-Fondazione 'G. Pascale', Naples, Italy.
Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori-Fondazione 'G.Pascale', Naples, Italy.
Ciliberto G; 'Regina Elena' National Cancer Institute, Rome, Italy.
Davies MA; Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
Ferrone S; Massachusetts General Hospital, Boston, MA, USA.
Gajewski TF; Department of Pathology and Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medicine, Chicago, IL, USA.
Garbe C; Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.
Luke JJ; The University of Chicago Medicine, Chicago, IL, USA.
Marincola FM; Refuge Biotechnologies, Menlo Park, CA, USA.
Masucci G; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Mehnert JM; Developmental Therapeutics Program, Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Mozzillo N; Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.
Palmieri G; Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy.
Postow MA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
Schoenberger SP; La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.
Wang E; Immune Oncology Discovery and System Biology, AbbVie, Redwood City, CA, USA.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2018 Jul 21; Vol. 16 (1), pp. 207. Date of Electronic Publication: 2018 Jul 21.
Typ publikacji:: Congress; Research Support, Non-U.S. Gov't
MeSH Terms:: Melanoma/*pathology
Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; Humans ; Immunotherapy ; Melanoma/immunology ; Models, Biological ; Systems Biology

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.
Autorzy:: Sinnberg T; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany. .
Levesque MP; Department of Dermatology, Universitaets Spital Zürich, Gloriastrasse 31, 8091, Zürich, Switzerland.
Krochmann J; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany.
Cheng PF; Department of Dermatology, Universitaets Spital Zürich, Gloriastrasse 31, 8091, Zürich, Switzerland.
Ikenberg K; Institute of Clinical Pathology, University Hospital Zürich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland.
Meraz-Torres F; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany.
Niessner H; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany.
Garbe C; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany.
Busch C; Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, University of Tübingen, Liebermeisterstr.25, 72076, Tübingen, Germany. .; Dermateam, Bankstrasse 4, 8400, Winterthur, Switzerland. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2018 Feb 17; Vol. 17 (1), pp. 59. Date of Electronic Publication: 2018 Feb 17.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cell Movement*/drug effects
Cell Movement*/genetics
Phenotype*
Wnt Signaling Pathway*
Cell Transformation, Neoplastic/*metabolism
Melanoma/*etiology
Melanoma/*metabolism
Neural Crest/*metabolism
Animals ; Biomarkers ; Cell Adhesion ; Chick Embryo ; Disease Models, Animal ; Epithelial-Mesenchymal Transition/genetics ; Gene Knockdown Techniques ; Humans ; Melanoma/mortality ; Melanoma/pathology ; Melanoma, Experimental ; Mice ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Neural Crest/pathology ; Perylene/analogs & derivatives ; Perylene/pharmacology ; RNA, Small Interfering/genetics ; Zebrafish ; beta Catenin/genetics ; beta Catenin/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: 18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
Autorzy:: Seith F; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany. .
Forschner A; Department of Dermatology, Eberhard Karls University, Liebermeisterstrasse 25, 72076, Tuebingen, Germany.
Schmidt H; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.
Pfannenberg C; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.
Gückel B; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.
Nikolaou K; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.
la Fougère C; German Cancer Consortium (DKTK), Heidelberg, Germany.; Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, Eberhard Karls University, Otfried-Mueller-Strasse 14, 72076, Tuebingen, Germany.
Garbe C; Department of Dermatology, Eberhard Karls University, Liebermeisterstrasse 25, 72076, Tuebingen, Germany.
Schwenzer N; Diagnostic and Interventional Radiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2018 Jan; Vol. 45 (1), pp. 95-101. Date of Electronic Publication: 2017 Aug 22.
Typ publikacji:: Evaluation Study; Journal Article
MeSH Terms:: Positron-Emission Tomography*
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Melanoma/*diagnostic imaging
Aged ; Female ; Fluorodeoxyglucose F18 ; Humans ; Magnetic Resonance Imaging ; Male ; Melanoma/drug therapy ; Middle Aged ; Multimodal Imaging ; Radiopharmaceuticals

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.
Autorzy:: Gaiser MR; Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
Skorokhod A; Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany.
Gransheier D; Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany.
Weide B; Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany.
Koch W; BDS Koch, Schwetzingen, Germany.
Schif B; Roche Pharma AG, Grenzach-Wyhlen, Germany.
Enk A; Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany.
Garbe C; Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany.
Bauer J; Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Nov 27; Vol. 12 (11), pp. e0188602. Date of Electronic Publication: 2017 Nov 27 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Probability*
High-Throughput Nucleotide Sequencing/*methods
Melanoma/*genetics
Mutation/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Age Distribution ; Humans ; Melanoma/pathology ; Middle Aged ; Models, Genetic ; Ultraviolet Rays

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Autorzy:: Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, IRCCS Istituto Nazionale Tumori 'Fondazione G. Pascale', Naples, Italy. .; Istituto Nazionale Tumori di Napoli Fondazione 'G. Pascale', Via Mariano Semmola, 80131, Naples, Italy. .
Agarwala SS; Oncology & Hematology, St. Luke's University Hospital and Temple University, Bethlehem, PA, USA.
Ciliberto G; IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy.
Demaria S; Radiation Oncology and Pathology, Weill Cornell Medical College, New York City, NY, USA.
Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
Duong CPM; INSERM (National Institute of Health and Medical Research), Institut Gustave Roussy, Villejuif, France.
Ferrone S; Massachusetts General Hospital, Boston, MA, USA.
Formenti SC; Department of Radiation Oncology, Weill Cornell Medical College, New York City, NY, USA.
Garbe C; Division of Dermatologic Oncology, Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
Halaban R; Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
Khleif S; Georgia Cancer Center, Augusta University, Augusta, GA, USA.
Luke JJ; Department of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Mir LM; CNRS (National Center for Scientific Research, France), University Paris-Saclay, Gustave Roussy, Villejuif, France.
Overwijk WW; Division of Cancer Medicine, Department of Melanoma Medical Oncology-Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Postow M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Weill Cornell Medical College, New York, NY, USA.
Puzanov I; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
Sondel P; Pediatrics, Human Oncology and Genetics, University of Wisconsin, Madison, WI, USA.; UW Carbone Cancer Center, Madison, WI, USA.
Taube JM; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thor Straten P; Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Herlev, Denmark.
Stroncek DF; Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zarour H; Medicine, Immunology and Dermatology Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2017 Nov 16; Vol. 15 (1), pp. 236. Date of Electronic Publication: 2017 Nov 16.
Typ publikacji:: Congress; Historical Article
MeSH Terms:: Melanoma*/diagnosis
Melanoma*/etiology
Melanoma*/therapy
Biomedical Research/*trends
Cancer Vaccines/therapeutic use ; Combined Modality Therapy/trends ; History, 21st Century ; Humans ; Immunotherapy/trends ; Italy ; Lymphocytes, Tumor-Infiltrating/transplantation ; Precision Medicine/methods ; Systems Biology/trends ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation ; Translational Research, Biomedical/trends

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Impact of F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis.
Autorzy:: Forschner A; Department of Dermatology, Eberhard-Karls-University Tuebingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. .
Olthof SC; Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Tübingen, Germany.
Gückel B; Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Tübingen, Germany.
Martus P; Department of Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-University Tuebingen, Tübingen, Germany.
Vach W; Institute of Medical Biometry and Statistics, University Freiburg, Freiburg, Germany.
la Fougère C; Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-University Tuebingen, Tübingen, Germany.
Nikolaou K; Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Tübingen, Germany.
Keim U; Department of Dermatology, Eberhard-Karls-University Tuebingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
Eigentler TK; Department of Dermatology, Eberhard-Karls-University Tuebingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
Garbe C; Department of Dermatology, Eberhard-Karls-University Tuebingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
Pfannenberg C; Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Tübingen, Germany.; Pokaż więcej
Źródło:: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2017 Aug; Vol. 44 (8), pp. 1312-1318. Date of Electronic Publication: 2017 Mar 18.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Fluorodeoxyglucose F18*
Metastasectomy*
Positron Emission Tomography Computed Tomography*
Melanoma/*pathology
Melanoma/*surgery
Aged ; Biomarkers, Tumor/metabolism ; Female ; Humans ; Male ; Melanoma/diagnostic imaging ; Melanoma/metabolism ; Middle Aged ; Neoplasm Staging ; Survival Analysis ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: GSTP1 does not modify MC1R effects on melanoma risk.
Autorzy:: Daley GM; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.
Duffy DL; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
Pflugfelder A; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.; Department of Dermatology, University Medical Center, Tuebingen, Germany.
Jagirdar K; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.
Lee KJ; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.
Yong XLH; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.
Eigentler TK; Department of Dermatology, University Medical Center, Tuebingen, Germany.
Weide B; Department of Dermatology, University Medical Center, Tuebingen, Germany.
Smithers BM; Queensland Melanoma Project, Princess Alexandra Hospital, Mater Research Institute, The University of Queensland, Brisbane, Qld, Australia.
Martin NG; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
Garbe C; Department of Dermatology, University Medical Center, Tuebingen, Germany.
Soyer HP; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Old, Australia.
Sturm RA; Dermatology Research Centre, The University of Queensland School of Medicine, Translational Research Institute, Brisbane, Qld, Australia.; Pokaż więcej
Źródło:: Experimental dermatology [Exp Dermatol] 2017 Aug; Vol. 26 (8), pp. 730-733. Date of Electronic Publication: 2017 Mar 23.
Typ publikacji:: Letter; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:: Glutathione S-Transferase pi/*genetics
Melanoma/*genetics
Receptor, Melanocortin, Type 1/*genetics
Genetic Predisposition to Disease ; Humans

Raport

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Autorzy:: Niessner H; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Kosnopfel C; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Sinnberg T; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Beck D; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Krieg K; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Wanke I; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Lasithiotakis K; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Bonin M; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Garbe C; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
Meier F; Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.; Department of Dermatology, Carl Gustav Carus Medical Center, TU Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.; Pokaż więcej
Źródło:: Experimental dermatology [Exp Dermatol] 2017 Jul; Vol. 26 (7), pp. 598-606.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dacarbazine/*analogs & derivatives
Intercellular Signaling Peptides and Proteins/*metabolism
Melanoma/*drug therapy
Sirolimus/*analogs & derivatives
Skin Neoplasms/*drug therapy
Antineoplastic Agents, Alkylating/administration & dosage ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Cell Survival ; Dacarbazine/administration & dosage ; Dacarbazine/therapeutic use ; Early Growth Response Protein 1/metabolism ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Gene Transfer Techniques ; Humans ; Indoles/administration & dosage ; Lentivirus ; Melanoma/metabolism ; Membrane Proteins/metabolism ; Oligonucleotide Array Sequence Analysis ; Signal Transduction ; Sirolimus/administration & dosage ; Sirolimus/therapeutic use ; Skin/metabolism ; Skin Neoplasms/metabolism ; Sulfonamides/administration & dosage ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; TOR Serine-Threonine Kinases/metabolism ; Temozolomide ; Vemurafenib

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Garbe, Claus"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji